Tags

Type your tag names separated by a space and hit enter

Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Am J Gastroenterol. 1987 Jun; 82(6):504-6.AJ

Abstract

Famotidine is a potent H2 receptor antagonist containing a thiazole ring structure, thus differing chemically from cimetidine and ranitidine. Pharmacologically, famotidine is nine times more potent than ranitidine and 32 times more potent than cimetidine. In the Zollinger-Ellison syndrome famotidine is more potent than cimetidine or ranitidine and has a 30% longer duration of action. Randomized double-blind controlled duodenal ulcer studies reveal famotidine effectively heals active ulcers when compared to placebo and that healing rates are comparable to those seen at 8 wk with ranitidine. Famotidine effectively heals gastric ulcers in 8 wk when compared to placebo. The drug also significantly reduced the recurrence rate of duodenal ulcers in a 6-month controlled trial. Famotidine is a potent H2 antagonist which appears to be safe at high doses, does not cause antiandrogen side effects, and does not interfere with hepatic oxidative metabolism. Further clinical experience will define famotidine's place in the therapeutic armamentarium against peptic ulcer disease.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2883885

Citation

"Famotidine. the ACG Committee On FDA-Related Matters With Primary Authorship By G. Friedman. American College of Gastroenterology." The American Journal of Gastroenterology, vol. 82, no. 6, 1987, pp. 504-6.
Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology. Am J Gastroenterol. 1987;82(6):504-6.
(1987). Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology. The American Journal of Gastroenterology, 82(6), 504-6.
Famotidine. the ACG Committee On FDA-Related Matters With Primary Authorship By G. Friedman. American College of Gastroenterology. Am J Gastroenterol. 1987;82(6):504-6. PubMed PMID: 2883885.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology. PY - 1987/6/1/pubmed PY - 1987/6/1/medline PY - 1987/6/1/entrez SP - 504 EP - 6 JF - The American journal of gastroenterology JO - Am J Gastroenterol VL - 82 IS - 6 N2 - Famotidine is a potent H2 receptor antagonist containing a thiazole ring structure, thus differing chemically from cimetidine and ranitidine. Pharmacologically, famotidine is nine times more potent than ranitidine and 32 times more potent than cimetidine. In the Zollinger-Ellison syndrome famotidine is more potent than cimetidine or ranitidine and has a 30% longer duration of action. Randomized double-blind controlled duodenal ulcer studies reveal famotidine effectively heals active ulcers when compared to placebo and that healing rates are comparable to those seen at 8 wk with ranitidine. Famotidine effectively heals gastric ulcers in 8 wk when compared to placebo. The drug also significantly reduced the recurrence rate of duodenal ulcers in a 6-month controlled trial. Famotidine is a potent H2 antagonist which appears to be safe at high doses, does not cause antiandrogen side effects, and does not interfere with hepatic oxidative metabolism. Further clinical experience will define famotidine's place in the therapeutic armamentarium against peptic ulcer disease. SN - 0002-9270 UR - https://www.unboundmedicine.com/medline/citation/2883885/Famotidine__The_ACG_Committee_on_FDA_Related_Matters_with_primary_authorship_by_G__Friedman__American_College_of_Gastroenterology_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.